Correlation Between Europlasma and Novacyt

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Europlasma and Novacyt at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Europlasma and Novacyt into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Europlasma SA and Novacyt, you can compare the effects of market volatilities on Europlasma and Novacyt and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Europlasma with a short position of Novacyt. Check out your portfolio center. Please also check ongoing floating volatility patterns of Europlasma and Novacyt.

Diversification Opportunities for Europlasma and Novacyt

0.9
  Correlation Coefficient

Almost no diversification

The 3 months correlation between Europlasma and Novacyt is 0.9. Overlapping area represents the amount of risk that can be diversified away by holding Europlasma SA and Novacyt in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novacyt and Europlasma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Europlasma SA are associated (or correlated) with Novacyt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novacyt has no effect on the direction of Europlasma i.e., Europlasma and Novacyt go up and down completely randomly.

Pair Corralation between Europlasma and Novacyt

Assuming the 90 days trading horizon Europlasma SA is expected to under-perform the Novacyt. In addition to that, Europlasma is 1.04 times more volatile than Novacyt. It trades about -0.9 of its total potential returns per unit of risk. Novacyt is currently generating about -0.15 per unit of volatility. If you would invest  66.00  in Novacyt on August 28, 2024 and sell it today you would lose (10.00) from holding Novacyt or give up 15.15% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Strong
Accuracy100.0%
ValuesDaily Returns

Europlasma SA  vs.  Novacyt

 Performance 
       Timeline  
Europlasma SA 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Europlasma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Novacyt 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Novacyt has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Europlasma and Novacyt Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Europlasma and Novacyt

The main advantage of trading using opposite Europlasma and Novacyt positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Europlasma position performs unexpectedly, Novacyt can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novacyt will offset losses from the drop in Novacyt's long position.
The idea behind Europlasma SA and Novacyt pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Transaction History
View history of all your transactions and understand their impact on performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
FinTech Suite
Use AI to screen and filter profitable investment opportunities